{"Clinical Trial ID": "NCT00591851", "Intervention": ["INTERVENTION 1:", "AC followed by Paclitaxel + Trastuzumab", "Doxorubicin and Cyclophosphamide (60/600 mg/m2) X 4 followed by Paclitaxel (175 mg/m2) X 4 every other week with pegfilgrastim (6 mg per day 2) + Trastuzumab x 1 year."], "Eligibility": ["Incorporation criteria:", "Adenocarcinoma breast cancer", "ECOG performance status of 0 or 1", "Peripheral neuropathy less than or equal to 1", "Discontinuation of hormonal treatment as chemoprevention during study", "LVEF by MUGA > 55%?", "Absolute number of neutrophils (ANC) > 1000/\u03bcL", "Number of platelets > 100 000/\u03bcL)", "- SGOT or SGPT < 92.5 units/L", "- Exclusion criteria:", "Stage IV breast cancer", "CURRENT breast cancer chemotherapy, radiation therapy, immunotherapy or biotherapy", "Pregnant or lactating patients", "A second active malignancy, other than adequately treated non-melanoma skin cancer or cervical cancer in situ", "Do you have an allergy/hypersensitivity prior to doxorubicin, cyclophosphamide, paclitaxel or other medicines formulated in Cremophor EL?", "Angor unstable, congestive heart failure, current use of digitalis, beta blockers or calcium blockers for the treatment of congestive heart failure, arrhythmia requiring medical treatment, or a history of myocardial infarction within 12 months", "A psychiatric illness that prevents him from understanding the nature of this study and complying with the requirements of the protocol?", "\u2022 Unresolved active infections", "\u2022 Sensitivity to E. coli-derived proteins", "Previous chemotherapy with anthracycline", "Prior treatment with Herceptin"], "Results": ["Performance measures:", "- Cardiac Saftey", "- LVEF per Muga scan", "Time limit: 18 months reference", "Results 1:", "Title of arm/group: AC followed by Paclitaxel + Trastuzumab", "Description of the arm/group: Doxorubicin and Cyclophosphamide (60/600 mg/m2) X 4 followed by Paclitaxel (175 mg/m2) X 4 every 2 weeks with pegfilgrastim (6mg on day 2) + Trastuzumab x 1 year.", "Total number of participants analysed: 70", "Median (full range)", "Unit of measurement: percentage of LEVF at reference level: 68 (55-81)", "- 2-month LVEF: 67 (58-79)", "6th month (67/70 pts): 66 (52-75)", "- LVEF at month 9 (68/70 pts): 65 (50-75)", "LVEF at month 18 (48/70 pts): 66 (57-75)"], "Adverse Events": ["Undesirable Events 1:", "Total: 19/70 (27.14 per cent)", "Febrile Neutropenia 24/70 (5.71%)", "Pericarditis 21/70 (1.43%)", "Sinus bradycardia 21/70 (1.43%)", "Abdominal pain 2/70 (2.86%)", "Diarrhoea 21/70 (1.43%)", "- Lower gastrointestinal haemorrhage 21/70 (1.43%)", "Nausea 21/70 (1.43%)", "Non-heart pain-Chest 22/70 (2.86%)", "Fever 24/70 (5.71 per cent)", "- Skin infection 41/70 (1.43%)", "- Decrease in neutrophil count 31/70 (1.43%)"]}